D-Wave Quantum: A 91.90% Lab Score, a Korean Handshake and a November 10 Verdict
Published on 11/03/2026 at 15:12 | Editorial boerse-global.de
D-Wave Quantum has spent the past week stacking up research wins and partnership announcements. None of them, however, answers the question investors keep circling back to: when does any of this turn into revenue? The company's third-quarter 2026 results, due before the opening bell on November 10, 2026, are the next scheduled moment when the business side gets to stand next to the science.
A preliminary result, not a clinical proof
Researchers at Florida Atlantic University put D-Wave's quantum annealing hardware to work on lung cancer prediction using limited data. A support vector machine model run on that hardware hit an accuracy of 91.90%, and the university said D-Wave's systems delivered the highest accuracy within the study.
The caveats matter as much as the headline number. The university explicitly labelled the findings preliminary, and the work rested on a dataset expanded with additional data as well as a chosen evaluation method. That makes the result a signal of where the technology might be useful — not a demonstration of performance in day-to-day medical practice. A hit rate on its own also says nothing about what D-Wave earns from it.
Shionogi's ¥40 million prize
A second health-sector datapoint landed on October 28, when D-Wave disclosed that customer Shionogi won the quality-of-life category at Japan's NEDO Quantum Computing Challenge. Shionogi's entry used quantum computing research for drug discovery, and the 40 million ¥ prize is meant to fund further work.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
The two items are different kinds of evidence. One is an award for research; the other is a result produced under specific test conditions. Both point to concrete applications, and neither yet translates into a financial contribution for D-Wave.
Korea: broad scope, no binding commitment
The same day brought the LG CNS letter of intent, signed October 28 and explicitly non-binding. The two companies intend to develop quantum optimization applications spanning manufacturing, telecommunications, finance and retail, aimed at South Korea and international markets, with joint marketing possibilities on the table.
The breadth is the interesting part — it points at operational business problems rather than raw technical benchmarks, and it opens a wide field to search. But a letter of intent documents shared development intentions. It carries less weight than a binding commercial order, and the sector spread is no substitute for economic commitment. What would move the needle is a concrete application turning into a durable business relationship.
D-Wave Quantum at a turning point? This analysis reveals what investors need to know now.
Reading Friday's tape correctly
Reuters attributed Friday's share price decline primarily to a broader technology selloff rather than to fresh company-specific bad news. The stock posted a daily move of -5.7%. Keeping those two things apart cuts both ways: a weak sector backdrop does not invalidate the LG CNS opportunity, and a letter of intent does not financially validate the business model. Neither does the study explain the share price move.
The measuring stick stays economic
Taken together, the week's announcements argue that D-Wave is engaged with practical use cases. They do not justify equating scientific recognition with commercial success. The LG CNS agreement is a sensible development step, not a commercial breakthrough, and a convincing re-rating would need to rest on more than the breadth of possible applications. November 10 is when the economic picture gets its next hearing.
Ad
D-Wave Quantum Stock: New Analysis - 3 November
Fresh D-Wave Quantum information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
